Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Suspended 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Lymphoid 2

Conditions

Carcinoma, Non-Small-Cell Lung 244Squamous Cell Carcinoma of Head and Neck 137Melanoma 136Parkinson Disease 4, Autosomal Dominant Lewy Body 119Neoplasm Metastasis 105Triple Negative Breast Neoplasms 96Neoplasms 90Lung Neoplasms 89Breast Neoplasms 79Colorectal Neoplasms 71Carcinoma, Renal Cell 69Head and Neck Neoplasms 59Urinary Bladder Neoplasms 51Stomach Neoplasms 49Ovarian Neoplasms 46Carcinoma, Transitional Cell 46Endometrial Neoplasms 45Pancreatic Neoplasms 35Carcinoma, Hepatocellular 35Uterine Cervical Neoplasms 34Esophageal Neoplasms 27Prostatic Neoplasms 26Carcinoma 26Recurrence 25Carcinoma, Squamous Cell 25Sarcoma 24Brain Neoplasms 23Glioblastoma 22Cholangiocarcinoma 20Hodgkin Disease 19

Interventions

Cyclophosphamide 9Rituximab 5glofitamab 4Whole-Body Irradiation 4fludarabine phosphate 3fludarabine 3Mycophenolic Acid 3Melphalan 3Doxorubicin 3polatuzumab vedotin 2pirtobrutinib 2pembrolizumab 2obinutuzumab 2Tacrolimus 2Sirolimus 2Prednisone 2Lenalidomide 2Busulfan 2zanubrutinib 1venetoclax 1relmacabtagene autoleucel 1pegfilgrastim 1axicabtagene ciloleucel 1Weights and Measures 1Vincristine 1Triamcinolone 1Specimen Handling 1Receptors, Chimeric Antigen 1Prednisolone 1Peripheral Blood Stem Cell Transplantation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Dendritic Cell Sarcoma, Interdigitating × pembrolizumab × 1 year × Clear all
NCT03349450 2026-05-06

SPiReL

Sunnybrook Health Sciences Centre

Phase 2 Completed
25 enrolled 18 charts
LymphoidSarcoma

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Recurrence, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

NCT03316573 2026-02-10

Pembrolizumab in Neoplasms or Lymphomas

Dana-Farber Cancer Institute

Phase 2 Suspended
18 enrolled 16 charts
LymphoidSarcoma

Lymphoma, Dendritic Cell Sarcoma, Interdigitating, Dendritic Cell Sarcoma, Follicular, Histiocytic Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡